Tumor Lysis Syndrome After Platinum-based Chemotherapy in Castration-resistant Prostate Cancer With a BRCA2 Mutation: A Case Report

Clin Genitourin Cancer. 2019 Feb;17(1):e61-e64. doi: 10.1016/j.clgc.2018.09.001. Epub 2018 Sep 7.

Authors

Aline Bobato Lara Gongora¹, Felipe Sales Nogueira Amorim Canedo¹, André Luis Alves de Melo², Regis Otaviano Franca Bezerra³, Paula Fontes Asprino⁴, Anamaria Aranha Camargo⁴, Diogo Assed Bastos⁵

Affiliations

¹ Oncology Center, Hospital Sírio-Libanês, São Paulo, Brazil.
² Pathology Department, Hospital Sírio-Libanês, São Paulo, Brazil.
³ Radiology Department, Hospital Sírio-Libanês, São Paulo, Brazil.
⁴ Molecular Oncology Center, Hospital Sírio-Libanês, São Paulo, Brazil.
⁵ Oncology Center, Hospital Sírio-Libanês, São Paulo, Brazil. Electronic address: diogo.bastos@hsl.org.br.

PMID: 30270052
DOI: 10.1016/j.clgc.2018.09.001

No abstract available

Keywords: BRCA mutation; DNA damage repair; Platinum chemotherapy; Prostate cancer; Tumor lysis syndrome.

Publication types

Case Reports

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / adverse effects*
BRCA2 Protein / genetics*
Carboplatin / administration & dosage
Etoposide / administration & dosage
Humans
Male
Middle Aged
Mutation*
Prognosis
Prostatic Neoplasms, Castration-Resistant / drug therapy*
Prostatic Neoplasms, Castration-Resistant / genetics
Prostatic Neoplasms, Castration-Resistant / pathology
Tumor Lysis Syndrome / etiology*
Tumor Lysis Syndrome / pathology

Substances

BRCA2 Protein
BRCA2 protein, human
Etoposide
Carboplatin